A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients With Chronic Hepatitis B

Trial Profile

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients With Chronic Hepatitis B

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs ABI-H0731 (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 09 Jul 2018 According to an Assembly Biosciences media release, initial results from this study are anticipated in the first half of 2019.
    • 09 Jul 2018 According to an Assembly Biosciences media release, Douglas T. Dieterich, M.D., Director, Institute of Liver Medicine, Professor of Medicine at Mount Sinai, is a principal investigator of the study.
    • 02 Jul 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top